Clinical Trials When Semaglutide was injected subcutaneously once a week for 68 weeks, trial participants achieved significant weight loss and other health benefits summarized here: 86% of people achieved at least 5% weight loss, 70% at least 10%, over 50% at least 15%, and one-third at least 20% at 68 weeks 3.7-inch reduction in waist circumference 4.6 decrease in BMI 5 mmHg decrease in systolic blood pressure Lowered fasting blood glucose levels Reduced total cholesterol, VLDL, triglycerides and free fatty acids Lowered C-reactive protein levels (marker of inflammation) Reduced risk of heart attack and stroke Weight loss plateaued at 60 weeks Depicted in the following chart is the observed weight change from the trial: Cardiovascular Benefits In a 3297 type II diabetic patient trial, 83% of participants having cardiovascular disease and/or chronic kidney disease, showed an improvement of kidney function and a decrease in adverse events as follows: 6 Disease Placebo Semaglutide Stroke 2.7% 1.6% Heart attack 3.9% 2.9% CV death 8.9% 6.6% Side Effects and Safety The most common side effects include nausea, vomiting, diarrhea, and constipation
Ozempic FDA label 12.3, Wegovy FDA label 12.3, Rybelsus FDA label 12.3
Just needing month 2 Ive been a loyal fan of VITAstir brand products for several years now, and I must say, they never disappoint
We understand that every patients journey is different, which is why we offer personalized weight loss plans designed specifically for you
